Penack, Olaf; Dreger, Peter; Ajib, Salem et al.
Management of Patients Undergoing CAR-T Cell Therapy in GermanyONCOLOGY RESEARCH AND TREATMENT. Bd. 47. H. 3. 2024
Ruecker, Frank G.; Bullinger, Lars; Cocciardi, Sibylle et al.
Measurable residual disease monitoring in AML with <i>FLT3</i>-ITD treated with intensive chemotherapy plus midostaurinBLOOD ADVANCES. Bd. 8. H. 23. 2024 S. 6067-6080
Jilg, Stefanie; Schwaab, Juliana; Sockel, Katja et al.
MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patientsANNALS OF HEMATOLOGY. Bd. 103. H. 10. 2024 S. 4065-4077
Matasar, Matthew; Bartlett, Nancy L.; Shadman, Mazyar et al.
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II TrialCLINICAL LYMPHOMA MYELOMA & LEUKEMIA. Bd. 24. H. 4. 2024 S. 240-253
Schoepf, Julia; Uhrig, Sebastian; Heilig, Christoph E. et al.
Multi-omic and functional analysis for classification and treatment of sarcomas with FUS-TFCP2 or EWSR1-TFCP2 fusionsNATURE COMMUNICATIONS. Bd. 15. H. 1. 2024
Lin, Chun-Pu; Levy, Pierre L.; Alflen, Astrid et al.
Multimodal stimulation screens reveal unique and shared genes limiting T cell fitnessCANCER CELL. Bd. 42. H. 4. 2024
Suarez-Carmona, Meggy; Halama, Niels
Neoadjuvant combination immunotherapy in MSI/dMMR colorectal cancerTRENDS IN CANCER. Bd. 10. H. 12. 2024 S. 1093-1094
Herold, S; Haebe, S; Dreyling, M et al.
Neue Konzepte beim follikulären Lymphom – immunologische und zelluläre Ansätze erweitern die TherapielandschaftKompedium Hämatologie Onkologie, November 2024 (Thieme Verlag). 2024 S. 1-1
De Waele, Laure; Sakai, Kazuya; Mancini, Ilaria et al.
Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpuraJOURNAL OF THROMBOSIS AND HAEMOSTASIS. Bd. 22. H. 2. 2024 S. 493-502
Malinverni, Chiara; Bernardelli, Andrea; Glimelius, Ingrid et al.
Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD studyBLOOD. Bd. 144. H. 9. 2024 S. 1001-1009